Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.03 USD
Change Today +0.07 / 1.77%
Volume 418.0K
THLD On Other Exchanges
As of 8:10 PM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

threshold pharmaceuticals (THLD) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/9/14 - $5.41
52 Week Low
11/7/14 - $2.58
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

threshold pharmaceuticals (THLD) Related Businessweek News

No Related Businessweek News Found

threshold pharmaceuticals (THLD) Details

Threshold Pharmaceuticals, Inc., a biotechnology company, discovers and develops therapeutic agents that target tumor cells for the treatment of patients living with cancer in the United States. Its lead investigational small molecule is evofosfamide, which is in two Phase III clinical trials for the treatment of soft tissue sarcoma indication and pancreatic cancer; Phase II clinical trials for treating non-squamous non-small cell lung cancer; Phase II clinical trials for advanced melanoma and soft tissue sarcoma; Phase I/II clinical trials for multiple myeloma and pancreatic cancer; and Phase I clinical trials for the treatment of solid tumors, pancreatic cancer, and advanced solid tumors. The company is also involved in the study of evofosfamide in investigator sponsored trials, including Phase I/II clinical trials for glioblastoma; Phase II clinical trials for glioblastoma and pancreatic neuroendocrine tumors; and Phase I clinical trials for advanced kidney cancer or liver cancer. In addition, it engages in developing antiangiogenic therapies in various tumor types in human clinical trials; TH-4000, an investigational hypoxia-activated EGFR tyrosine kinase inhibitor; and [18F]-HX4, an investigational PET imaging agent for hypoxia. The company has a license and co-development agreement with Merck KGaA to co-develop and commercialize evofosfamide; license agreement with Auckland UniServices Ltd. for the development program based on TH-4000; and license agreement with Eleison Pharmaceuticals, Inc. for the manufacture, development, and commercialization of glufosfamide for the treatment of cancer in humans and animals, as well as other uses. Threshold Pharmaceuticals, Inc. was founded in 2001 and is headquartered in South San Francisco, California.

62 Employees
Last Reported Date: 04/30/15
Founded in 2001

threshold pharmaceuticals (THLD) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $575.0K
Vice President of Finance and Controller
Total Annual Compensation: $273.0K
Chief Medical Officer
Total Annual Compensation: $395.0K
Senior Vice President of Regulatory Affairs &...
Total Annual Compensation: $320.0K
Senior Vice President of Pharmaceutical Devel...
Total Annual Compensation: $290.0K
Compensation as of Fiscal Year 2014.

threshold pharmaceuticals (THLD) Key Developments

Threshold Pharmaceuticals, Inc. Announces Encouraging Preliminary Data from Phase II Myeloma Trial

Threshold Pharmaceuticals Inc. has announced encouraging preliminary data from the Phase II component of an ongoing Phase I/II trial of evofosfamide in combination with the proteasome inhibitor, Velcade, or bortezomib, and low-dose dexamethasone, or EBorD, in patients with relapsed/refractory multiple myeloma. A clinical benefit rate of 29% (one complete response, two partial responses, and one minimal response) was observed in patients treated at the recommended Phase II dose of evofosfamide (340 mg/m2) in EBorD. Objective responses were observed in heavily pretreated patients (median of 8 prior systemic therapy regimens) including prior treatment with bortezomib (median of 3 prior bortezomib-containing regimens). The ongoing Phase I/II trial is investigating evofosfamide and dexamethasone with or without bortezomib with respect to safety and tolerability, dose-limiting toxicities and the maximum-tolerated dose of evofosfamide, and preliminary efficacy in patients with relapsed/refractory multiple myeloma. The recommended Phase II dose of evofosfamide in EBorD was previously established at 340 mg/m2. A total of 25 patients with relapsed/refractory multiple myeloma have been enrolled in the EBorD component of the study as of May 1, 2015. Preliminary safety and tolerability results from the 18 patients included in the ASCO presentation support further investigation of evofosfamide in patients with relapsed/refractory multiple myeloma. The most common Grade 3/4 hematological adverse events were thrombocytopenia (reported in 11 patients), anemia (reported in 6 patients), and neutropenia (reported in 4 patients). Nausea (reported in 8 patients; one Grade 3/4) and fatigue (reported in 7 patients; one Grade 3/4) were the most common non-hematological adverse events. Eleven serious adverse events (SAEs) were reported in 9 patients. The only SAE occurring in more than one patient were two events of colitis. Neither event was considered related to evofosfamide. Five SAEs were considered as related to evofosfamide: bronchiolitis, melena, pneumonia, thrombocytopenia and viral infection. Skin toxicity and mucosal toxicities were not dose limiting. Rash was reported in five patients; stomatitis, skin lesion, pruritus and skin hyperpigmentation were each reported in one patient; none of these were Grade 3 or higher. No patients discontinued treatment due to an adverse event. There were no deaths related to study drug. Preliminary results from the 18 patients suggested anti-myeloma activity of EBorD therapy. According to modified International Myeloma Working Group (IMWG) criteria, responses included one complete response (CR), two partial responses (PRs), one minimal response (MR) and eleven stable disease (SD) assessments; three patients had progressive disease (PD). The patients with the CR and PRs had all previously undergone autologous transplantations and had received prior current standard treatment including IMiDs (a class of immunomodulators), proteasome inhibitors (including bortezomib), dexamethasone, and at least one conventional alkylating agent.

Threshold Pharmaceuticals Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 04:00 PM

Threshold Pharmaceuticals Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 04:00 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Harold E. Selick, Executive Chairman and Chief Executive Officer.

Threshold Pharmaceuticals, Inc. Announces New Clinical Data from Its Ongoing Phase 2 Clinical Trial

Threshold Pharmaceuticals Inc. announced that new clinical data from its ongoing Phase 2 clinical trial evaluating evofosfamide (previously known as TH-302), an investigational compound, with bortezomib (Velcade(r)) and dexamethasone in patients with relapsed/refractory multiple myeloma.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
THLD:US $4.03 USD +0.07

THLD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for THLD.
View Industry Companies

Industry Analysis


Industry Average

Valuation THLD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THRESHOLD PHARMACEUTICALS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at